ExpressPoints: Expert Guidance and Resources to Personalize Care and Improve Outcomes for Patients with RCC

Download this short summary slideset of key takeaways from this CCO program focused on current individualized management of patients with metastatic RCC.
Brian A. Costello, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 1.02 MB
Released: December 31, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Bristol-Myers Squibb

Related Content

Downloadable slides with notes from pharmacist and nursing experts on maintenance avelumab, enfortumab vedotin and erdafitinib for urothelial carcinoma, from CCO

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Released: January 11, 2021

Simplified treatment option resource for advanced urothelial carcinoma highlighting recently approved agents, from Clinical Care Options (CCO)

person default Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Released: January 7, 2021

CCO guide on signs and symptoms of potential AEs for your patients receiving erdafitinib or enfortumab vedotin

person default Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Released: January 6, 2021

From Clinical Care Options (CCO), watch this short video on optimal management of common AEs seen with enfortumab vedotin treatment in patients with advanced urothelial carcinoma

Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 22, 2020 Expired: December 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue